Sobi™ launches Ravicti® in Europe and advances the care for patients with Urea Cycle Disorders
Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the company has gained reimbursement for Ravicti®, a new therapy option for the treatment of patients with Urea Cycle Disorders (UCDs) in several EU member states and EEA-countries. Sweden, Denmark, Austria and Germany are the first countries to launch, followed by UK, Spain and the Netherlands. “We are very pleased that Ravicti is gaining reimbursement in countries across Europe for patients with Urea Cycle Disorders”, said Norbert Oppitz, Head of Specialty Care at Sobi. “The reimbursement enables us to